Company Announcements

Half-year report

Downing FOUR VCT plc 
LEI: 21380035MV1VRYEXPR95 
Half-Yearly Report for the six months ended 30 September 2021
13 December 2021

 UnauditedAuditedUnaudited
 30
September
2021
31
March
2021
30
September
2020
 pencepencepence
    
Ventures Share pool   
Net Asset Value per Ventures Share68.5067.261.2
Cumulative distributions5.252.52.5
Total Return per Ventures Share73.7569.763.7
    
Healthcare Share pool   
Net Asset Value per Healthcare Share88.7068.565.2
Cumulative distributions5.252.52.5
Total Return per Healthcare Share93.9571.067.7
    
DSO D Share pool   
Net Asset Value per DSO D Share10.210.210.7
Cumulative distributions94.594.594.5
Adjusted for Performance Incentive estimate1(0.3)(0.5)(1.2)
Total Return per DSO D Share104.4104.2104.0
    
DP67 Share pool   
Net Asset Value per DP67 Share19.518.418.4
Cumulative distributions (since original launch)67.867.867.8
Total Return per DP67 Share87.386.286.2
  1. Based on Total Return to Shareholders at 30 September 2021, a Performance Incentive is expected to become due to management. The Performance Incentive has been estimated at 0.3p per DSO D Share. No provision has been included in the accounts as the conditions of the Performance Incentive fee have not yet been met.

Chairman’s Statement

Introduction

I am pleased to present the Company’s Half-Yearly Report for the six months ended 30 September 2021.

This has been a busy period for your Company, with a new evergreen share class created, another share class renamed and a new offer for subscription launched. We were also pleased to welcome three new board members and saw good progress made by some of the evergreen portfolio companies.

Fundraising
In August, the Company published a shareholder circular seeking approval for various resolutions in connection with the launch of a new fundraising. A new evergreen share class, focussing on AIM-quoted investments, was proposed, as well as a change of name for the Generalist Share class to become the Ventures Share Class to better describe the focus of its activities. A general meeting took place on 21 September 2021 at which all resolutions were passed.

The new offer for subscription was launched at the same time, seeking to raise up to £10M in each of the Ventures, Healthcare and AIM share classes, with an overallotment facility of up to £15M for each share class.

The Board believes that the Company offers an attractive proposition for VCT investors, as there are signs that some of the earlier investments in the Ventures and Healthcare portfolio are starting to mature and the AIM market is also providing good opportunities for investment.

Full details of the offer can be found on the Downing website:

downing.co.uk/investor/products/vct

No shares have yet been allotted under this offer and therefore the AIM Share class does not feature in this Half-Yearly Report. We expect the Annual Report for the year ended 31 March 2022 to be the first report to cover the AIM Share class.

Evergreen Share pool review
Ventures Share pool (formerly Generalist)
During the period, the Ventures Share pool made one follow-on investment of £125,000, and there was an IPO which involved the conversion of loan notes into equity.

The Ventures Share pool Total Return stood at 73.75p as at 30 September 2021. This is an increase of 4.05p or 6.0% over the period, after adjusting for the dividend of 2.75p per Ventures Share, paid on 24 September 2021.

The NAV increase for the period predominantly results from several valuation uplifts within the Venture Capital Portfolio, including the IPO of Arecor Therapeutics plc (“Arecor”), which is discussed in more detail in the Investment Manager’s Reports for the Ventures and Healthcare Share pools.

Within the Ventures Liquidity Portfolio, there was a further redemption from MI Downing UK Micro-Cap Growth Fund, which is in the process of winding up. Downing Strategic Micro-Cap Investment Trust performed well over the period, increasing in value by over 6%, and there have been further positive updates.

A more detailed review of the Ventures Share pool is included in the Ventures Investment Manager’s Report. A review of the Liquidity Investments is included below.

Healthcare Share pool
During the period, the Healthcare Share pool invested £1.2 million in four VCT Qualifying companies, three of which were existing companies in the Healthcare Share pool’s Venture Capital Portfolio. There were also two IPOs during the period, which are discussed in more detail in the Investment Manager’s Report.

As at 30 September 2021, the Healthcare Share pool Total Return stood at 93.95p. This is an increase of 22.95p or 33.5% over the period, after adjusting for the dividend of 2.75p per Healthcare Share, paid on 24 September 2021.

The NAV increase for the period is largely attributable to the AIM IPOs of two portfolio companies: Arecor and GENinCode. Based on their quoted share prices as at 30 September 2021, Arecor and GENinCode generated unrealised valuation gains totalling £3.5 million for the period. The remaining investments in the Healthcare Venture Capital Portfolio generated unrealised valuation gains of £1.1 million for the period.

As with the Ventures Share pool, the Healthcare Share pool received a further redemption from MI Downing UK Micro-Cap Growth Fund, which is in the process of winding up. Downing Strategic Micro-Cap Investment Trust also performed well over the period, as noted above, increasing in value by over 6%.

A more detailed review of the Healthcare Share pool is included in the Investment Manager’s Report. A review of the Liquidity Investments is included below.

Planned Exit Share pools
DSO D Share pool
The DSO D Share pool holds four remaining investments. At the period end, the net asset value per share (“NAV”), net of the estimated performance incentive fee, stood at 9.9p. Total Return at 30 September 2021 stood at 104.4p per share, an increase of 0.2p since 31 March 2021.

After the half-year date, the Manager achieved exits from the DSO D Share pool’s two renewable energy investments at proceeds slightly exceeding their valuations as at 30 September 2021. As a result of these exits, the Company is in a position to declare a dividend to DSO D Shareholders, which I will come on to mention.

The Manager is also progressing plans to exit from the two businesses with exposure to the hospitality sector, Pearce and Saunders Limited and Pearce and Saunders DevCo Limited. It is expected that these two investments will exit in 2022.

A more detailed review of the DSO D Share pool is included in the Investment Manager’s Report.

DP67 Share pool
The DP67 Share pool also holds four remaining investments. At the period end, the net asset value (“NAV”) per Share stood at 19.5p. Total Return at 30 September 2021 stood at 87.3p per share, an increase of 1.1p per share since 31 March 2021.

The DP67 Share pool has significant exposure to the hospitality sector and it has not been possible to significantly progress exits from these businesses yet, as they are only just starting to re-establish trading records following the disruption of the pandemic. However, with the UK economy continuing to open up and lockdown restrictions looking to be behind us, the Manager is now targeting an exit by the end of 2022.

A more detailed review of the DP67 Share pool is included in the Investment Manager’s Report.

Dividends
On 24 September 2021, the Company paid dividends in respect of the year ended 31 March 2021, of 2.75p per Ventures Share and 2.75p per Healthcare Share. This brings the total dividends paid to date on each of the Ventures and Healthcare Share pools, to 5.25p each.

Following the exits from Fresh Green Power and Green Energy Production, after the half-year date, the DSO D Share pool is now in a position to declare a 7.5p dividend to DSO D Shareholders, to be paid on 28 January 2022, to Shareholders on the register as at 7 January 2022.

For both the DSO D and DP67 Share pools, the next dividends will be declared once further realisations have taken place.

Board reorganisation
With much of the Company’s activity now focussed on the evergreen share pools which invest in young growth businesses, a review of the board composition was undertaken, to ensure it was well aligned with the Company’s needs going forward.

A formal process took place with an external recruitment consultant to identify suitable candidates with experience relevant to areas in which the Company now actively invests. Full consideration was given to board diversity as part of this process; however, the primary criteria was to identify the candidates best placed to make a meaningful contribution to the Company in its investing activities.

Ultimately two candidates from this process were invited to join the board and were appointed as non-executive directors on 8 September 2021.

Steven Clarke has 30 years’ experience of investing in technology and data businesses including 21 years as a private equity investor with 3i, August Equity and ICG. Steven now supports founders through fundraising, international growth and exit as an investing non-executive director usually alongside a growth equity fund. Steven is also chair of the investment committee for Bethnal Green Ventures, a Tech for Good impact investor.

Dr Andrew Mackintosh has had a distinguished career in industry and investment as a former CEO of FTSE 250 company, Oxford Instruments, before later leading the creation of the Royal Society Enterprise Fund, a pioneering initiative in bringing together scientific expertise and early-stage investment. He was a Board Member of the Intellectual Property Office and a trustee of the Design Council and is currently chairman of Sphere Fluidics Limited, a high-growth biotechnology tools company. He is also chairman of UKI2S, a government-backed venture capital fund supporting companies from the UK’s scientific research base.

Andrew has a longstanding interest in enhancing the commercialisation and wider economic impact of UK research and is the author of a report (‘The Mackintosh Report’) commissioned by HM Treasury and published in April 2021.

In addition to the above, in order to enhance the operational relationship between the Board and the Manager, Chris Allner, partner of Downing LLP, also joined the board on 8 September 2021 as a non-executive director. No remuneration will be paid by the Company in respect of his role.

Chris has 35 years of venture capital and private equity experience, previously as head of private equity at Octopus Investments. Prior to this, he was a director at Beringea and Bridgepoint with previous experience at 3i and Charterhouse. Chris has transacted over 50 investments and has sat on the boards of a number of unquoted and quoted portfolio companies across a variety of commercial sectors.

Alongside the above appointments, Russell Catley stepped down as a non-executive director of the Company on 8 September 2021. Russell joined the Company’s board following the merger with three other VCTs in 2015. We thank Russell for his valuable contributions throughout his tenure and will miss his sage and intelligent advice. We wish him all the very best in his future activities.

I believe we now have a board of directors with a broad range of skills and experience that is well suited to oversee the Company during the next years of its life.

Share buybacks
The Company operates a general policy of buying in Shares from its Evergreen Share pools that become available in the market, subject to regulatory and liquidity factors. Any such purchases are undertaken at a price approximately equal to NAV (i.e. at a nil discount).

As the planned exit share classes are in the process of returning funds to Shareholders, the Company no longer operates a share buyback policy in respect of the DSO D and DP67 Share classes.

During the six-month period ended 30 September 2021, the Company repurchased 15,924 Ventures Shares and 16,990 Healthcare Shares, at average prices of 67.2p and 81.6p per share, respectively.

If you wish to sell or buy Shares in the Company, Panmure Gordon can supply details of closed periods etc.

Outlook
The Board is very encouraged by the progress made by the Healthcare share pool in recent months where two of the portfolio companies have started to demonstrate their potential in successfully completing IPOs. There are also signs within the Ventures share pool of the stronger investments starting to make headway. Both share pools suffered some setbacks in their early years. This is not an unexpected feature of investing in a portfolio of young businesses where investments may take time to prove their worth. This performance was also compounded by the impact of the coronavirus pandemic. With many of the businesses in these portfolios now several years into their life and having dealt with challenging conditions, we believe there are good prospects for improved overall performance going forward.

The new offer for subscription should ensure that the Company has funds available to allow the evergreen share classes to take advantage of attractive new investment opportunities which the Investment Manager is seeing, including extending into the area of AIM-quoted companies with the new AIM Share class.

For the planned exit share pools, the ongoing delays in exiting the investments are disappointing but somewhat expected given the sectors in which these shares classes are invested and the impact of the pandemic. The Board is satisfied that the Manager’s strategy in working towards exits while seeking to achieve optimal values is sensible. We hope to see progress in completing the task of realising the investments over the next 12 months.

I look forward to updating all Shareholders in my statement with the Annual Report, which we expect to publish in July 2022.

Sir Aubrey Brocklebank Bt.

Chairman

Investment Manager’s Report - Ventures Share Pool

i.  Overview

Introduction
We present a review of the investment portfolio and activity for the Ventures Share pool over the six-month period to 30 September 2021.

This Investment Manager’s Report is split into two sections comprising this overview and a review of the Venture Capital Portfolio. Where the Ventures Share pool has invested alongside the Healthcare Share pool, further valuation commentary can be found within the Investment Manager’s Report for the Healthcare Share pool.

A separate report on the portfolio of Liquidity Investments is included below.

Net Asset Value and results
As at 30 September 2021, the NAV of a Ventures Share stood at 68.5p, an increase of 4.05p from 31 March 2021, after adding back the dividend of 2.75p which was paid during the period.

The return on ordinary activities for the Ventures Share pool for the period was £1.97 million, comprising a revenue loss of £253,000 and a capital gain of £2.2 million.        

Whilst there has been further recovery in the NAV since 31 March 2021, the Total Return to Shareholders as at 30 September 2021, of 73.75p, continues to be considered an underperformance against our expectations for the Ventures Share pool.

Portfolio Overview
As at 30 September 2021, the Ventures Share pool held a portfolio of 36 Venture Capital investments and two Liquidity investments, with a total carrying value of £30.8 million.

Portfolio Performance
Overall, there were ten valuation increases in the Venture Capital Portfolio, totalling £4.4 million, which more than offset the eight valuation reductions, totalling £2.2 million. The net valuation increase across the Venture Capital Portfolio was therefore £2.2 million as at 30 September 2021.

The carrying values of the Liquidity Investments have been adjusted to reflect their quoted prices as at 30 September 2021. This resulted in a valuation uplift of £180,000 for the half-year period. Liquidity Investments are discussed in more detail below.

ii.  Venture Capital Portfolio

Investment activity
During the period, £125,000 was invested in one existing business in the Venture Capital Portfolio. There was also one conversion within the portfolio, of loan notes into equity.

Follow-on Venture Capital investments
FVRVS Limited, trading as Fundamental VR, provides surgery simulation software for
enterprise clients and hospitals. The Ventures Share pool invested an additional £125,000 in the business, alongside a further £250,000 from the Healthcare Share pool.

On 3 June 2021 Arecor Therapeutics plc (“Arecor”) undertook a successful IPO on AIM. As part of the IPO, the Ventures Share pool’s existing loan note holding was converted into ordinary shares.

Portfolio valuation
During the period, the Venture Capital portfolio of the Ventures Share pool was increased in value by a total of £2.2 million, following a number of positive developments.

E-Fundamentals (Group) Limited, a Software as a Service (SaaS) analytics company, which has developed and commercialised a SaaS analytics tool, has continued to grow its customer base, both in the UK and in the US, resulting in a valuation uplift of £1.3 million as at 30 September 2021.

Hackajob Limited, the owner of a marketplace platform for hiring technical talent, has progressed well during the period, with recurring revenues continuing to grow. The valuation was uplifted by £697,000 as at 30 September 2021 as a result.

The valuation of Arecor was uplifted by £634,000 as at 30 September 2021. Further valuation commentary can be found below.

Imagen Limited, the developer of a cloud-based enterprise video platform, has grown its revenues significantly from the time of the Ventures Share pool’s investment. In line with this continued growth, the investment in the business was uplifted by £524,000 as at 30 September 2021.

Ayar Labs, Inc., the developer of components for high performance computing and data centre applications, was uplifted in valuation by £465,000 as at 30 September 2021, including the impact of foreign exchange. This revaluation is the result of a calibration to the price set under a recent funding round.

Trinny London Limited, the e-commerce-based beauty and cosmetics brand launched by Trinny Woodall, has continued its strong performance, and was uplifted in value by £283,000 as at 30 September 2021.

Xupes Limited, a pre-owned luxury goods retailer specialising in designer watches, handbags and jewellery, was sold during October 2021, returning £675,000 to the Ventures Share pool. The valuation as at 30 September 2021 has been uplifted by £384,000 to reflect the sales proceeds achieved.

The Ventures Share pool’s investment in FVRVS Limited (trading as Fundamental VR) was uplifted by £64,000 as at 30 September 2021. Please see below for further valuation commentary.

Streethub Limited (trading as Trouva), an online marketplace for a curated range of homeware and lifestyle products, has been reduced in value by £503,000, as a result of the business trading behind budget.

Hummingbird Technologies Limited, the owner of an advanced crop analytics platform that is powered by machine learning and aerial imagery, was reduced in value by £482,000 as at 30 September 2021, on the back of a downgrade in revenue forecasts.

Empiribox Holdings Limited, a creator of practical resources for effective science lessons, was revalued to £nil as at 30 September 2021. The coronavirus pandemic added to the group’s existing challenges and ultimately led to its failure. The business is now in liquidation and it is disappointing to report that no value recovery is expected.

FundingXchange Limited, an SME funding platform and B2B technology provider which enables online lending, was subject to a valuation reduction of £264,000 as at 30 September 2021, as forecasted revenue performance is yet to materialise.

Exonar Limited, a developer of software solutions which help ensure compliance with data-centric regulations and imperatives, was reduced in value by £177,000 as at 30 September 2021. This is the result of a calibration to the price set under a recent funding round.

Destiny Pharma plc, which is listed on AIM, was reduced in value by £165,000 as at 30 September 2021. Please see below for further valuation commentary.

Lineten Limited, the owner of an aggregator platform for on-demand and same day delivery, was subject to a valuation reduction of £157,000 as at 30 September 2021. The business has progressed slowly and is revenue performance is behind Downing’s investment case.

The small valuation movements in respect of Virtual Class Limited (trading as Third Space Learning), Cornelis Networks, Inc., Parsable, Inc. and Carbice Corporation, offset one another for the half-year period, resulting in a net movement of £nil.

Outlook
After some early setbacks in the Liquidity and Venture Capital portfolios, we are now starting to see improved performance from the Ventures Share class, driven by a number of valuation uplifts. It is reassuring that most of the portfolio companies have weathered the pandemic and many may now be better placed than they were beforehand.

Our role over the remainder of the year will focus on continued support of the existing portfolio companies in the Venture Capital Portfolio, as well as looking to add new investments to this portfolio as the proceeds of the current fundraising become available.

Downing LLP

Review of Investments – Ventures Share Pool
The following investments were held at 30 September 2021:

 Cost as at
30 September
2021
Valuation as at
30 September
2021
Valuation
movement
in period


% of
portfolio
Portfolio of investments£’000 £’000 £’000 
Venture Capital investments    
E-Fundamentals (Group) Limited1,3423,6681,26011.0%
Imagen Limited1,0002,3525247.0%
Virtual Class Limited (t/a Third Space Learning)1,0531,816(60)5.4%
Rated People Limited1,2821,584-4.8%
Hackajob Limited7841,4816974.4%
Cornelis Networks, Inc.1,4021,337304.0%
Trinny London Limited2191,2402833.7%
Ayar Labs, Inc.7641,1914653.6%
Arecor Therapeutics plc^4181,0526343.2%
Firefly Learning Limited1,0471,047-3.1%
Ecstase Limited (t/a ADAY)1,0001,000-3.0%
Limitless Technology Limited757920-2.8%
FundingXchange Limited1,050786(264)2.4%
Streethub Limited (t/a Trouva)1,208770(503)2.3%
Congenica Limited734746-2.2%
Parsable, Inc.766694162.1%
Xupes Limited9336753842.0%
Masters of Pie Limited667667-2.0%
Carbice Corporation656623141.9%
JRNI Limited525525-1.6%
Maverick Pubs (Holdings) Limited1,000450-1.3%
FVRVS Limited (t/a Fundamental VR)375439641.3%
Fenkle Street LLP*301388-1.2%
Destiny Pharma plc^500364(165)1.1%
Cambridge Touch Technologies Limited459361-1.1%
Channel Mum Limited675278-0.8%
Hummingbird Technologies Limited750271(482)0.8%
Upp Technologies Group Limited (previously Volo Commerce)1,077242-0.7%
Exonar Limited550202(177)0.6%
MIP Diagnostics Limited200200-0.6%
Lineten Limited40052(157)0.2%
Empiribox Holdings Limited1,563-(405)0.0%
Lignia Wood Company Limited1,778--0.0%
Live Better With Limited1,211--0.0%
Ormsborough Limited900--0.0%
 29,34627,4212,15882.2%
Liquidity investments    
Downing Strategic Micro-Cap Investment Trust plc*^4,2693,33319610.0%
MI Downing UK Micro-Cap Growth Fund*12376(16)0.2%
 4,3923,40918010.2%
 33,73830,8302,33892.4%
Cash at bank and in hand 2,517 7.6%
Total investments 33,347 100.0%

All Venture Capital investments are incorporated in England and Wales.
*non-qualifying investment                
^listed and traded on the London Stock Exchange

Investment movements for the period ended 30 September 2021

 Cost
Additions £’000
Venture Capital investments 
Arecor Therapeutics plc**422
FVRVS Limited125
 547


 CostValuation at
01/04/21*
ProceedsLoss
vs. cost
Realised
gain
Disposals£’000£’000£’000£’000£’000
Venture Capital investments     
Glownet Limited741--(741)-
Arecor Limited**418418418--
Liquidity investments     
MI Downing UK Micro-Cap Growth Fund*369270301(68)31
 1,528688719(809)31

*non-qualifying investment
**includes Loan Note conversion and share for share exchange

Investment Manager’s Report- Healthcare Share Pool

i.  Overview

Introduction
We present a review of the investment portfolio and activity for the Healthcare Share pool over the six-month period to 30 September 2021.

This Investment Manager’s Report is split into two sections comprising this overview and a review of Venture Capital Portfolio.

A separate report on the portfolio of Liquidity Investments is included below.

Net Asset Value and results
As at 30 September 2021, the NAV of a Healthcare share stood at 88.70p, an increase of 22.95p from 31 March 2021, after adding back the dividend of 2.75p which was paid during the period.

The return on ordinary activities for the Healthcare Share pool for the period was £4.5 million, comprising a revenue loss of £132,000 and a capital gain of £4.6 million.

The Total Return to Healthcare Shareholders, as at 30 September 2021, was 93.95p.

Portfolio Overview
As at 30 September 2021, the Healthcare Share pool held a portfolio of 13 Venture Capital investments and two Liquidity investments, with a combined value of £15.4 million.

The valuation movements during the period are discussed in more detail in the following sections of this Investment Manager’s Report.

Portfolio Performance
There were a number of valuation movements in the Venture Capital Portfolio during the period, resulting in a net valuation increase of £4.7 million.

The carrying values of the Liquidity Investments have been adjusted to reflect their quoted prices as at 30 September 2021. This resulted in a valuation uplift of £29,000 for the period. Liquidity Investments are discussed in more detail below.

ii.  Venture Capital Portfolio

Investment activity
During the period, a total of £1.2 million was invested in four VCT Qualifying companies, three of which were existing businesses within the Venture Capital Portfolio. There were also two IPOs on AIM, one of which involved the conversion of loan notes into equity.

New Venture Capital investments
DiA Imaging Analysis Limited (“DiA”) (£415,000) is a leading provider of advanced AI-based solutions for ultrasound analysis. The additional capital will enable DiA to expand its portfolio of FDA-cleared and CE-marked AI-based ultrasound solutions that enable clinicians to identify clinical abnormalities with speed and accuracy.

Follow-on Venture Capital investments
GENinCode plc (“GENinCode”) develops products and technology that helps patients and healthcare practitioners to assess and predict the onset of cardiovascular disease, thrombosis, and the diagnosis of Familial Hypercholesterolemia. As part of the Company’s IPO on 22 July 2021, the Healthcare Share pool made a follow-on investment of £302,000 in the business.

FVRVS Limited, trading as Fundamental VR, provides surgery simulation software for enterprise clients and hospitals. The Healthcare Share pool invested an additional £250,000 in the business, alongside a further £125,000 from the Ventures Share pool.

The Electrospinning Company Limited is a supplier and manufacturer of clinical-grade biomaterials, which can be used to act as a synthetic scaffold for implantation within body tissue to promote repair post trauma or surgery. During the period the Healthcare Share pool invested a further £200,000 in the business.

On 3 June 2021 Arecor Therapeutics plc (“Arecor”) undertook a successful IPO on AIM (see portfolio valuation commentary). As part of the IPO, the Healthcare Share pool’s existing loan note holding was converted into ordinary shares.

Portfolio valuation
As at 30 September 2021, the Venture Capital portfolio of the Healthcare Share pool was increased in value by a total of £4.7 million.

Since its IPO, Arecor has made several positive updates on the progress of its products, which have bolstered its share price. As at 30 September, the market capitalisation of Arecor was £116 million. With the valuation now being based on the quoted bid price, the valuation of the Healthcare Share pool’s investment in the group was uplifted by £2.3 million as at 30 September 2021.

GENinCode successfully admitted its shares to trading on AIM on 22 July 2021, taking the market capitalisation of the company to approximately £42 million at that date. The company’s quoted share price has been relatively flat since September 2021, as a result of limited news flow from the company, although a number of positive developments were announced alongside the interim results, released on 16 September 2021. In line with the quoted bid price as at 30 September 2021, the Healthcare Share pool’s holding in GENinCode was increased by £1.2 million.

Adaptix Limited is a developer of a flat panel X-ray source which seeks to improve the accuracy and mobility of 3D imaging. The company’s technology will make portable, low radiation dose 3D imaging more accessible and lower cost than systems currently available on the market. The valuation of the company has been uplifted, as a result of a recalibration of the valuation in line with a recent funding round. The uplift in the carrying value of the Healthcare Share pool’s investment, as at 30 September 2021, was £758,000.

Open Bionics Limited is an award-winning designer, manufacturer and supplier of bionic limbs. The company uses 3D printing and scanning technology to produce custom-made prosthetics at a lower manufacturing cost relative to existing technologies. The valuation of the business has been uplifted in accordance with an external valuation. The resulting uplift for the Healthcare Share pool was £378,000 as at 30 September 2021.

The valuation of FVRVS Limited (trading as Fundamental VR) has been increased as a result of a calibration to the most recent funding round. The valuation uplift for the Healthcare Share pool was £129,000 as at 30 September 2021.

The carrying value of the Healthcare Share pool’s investment in The Electrospinning Company Limited was increased by £124,000 as at 30 September 2021. This is reflective of a calibration to the company’s recent funding round, in which the Healthcare Share pool partook.

Destiny Pharma plc, which is listed on AIM, was reduced in value by £248,000 as at 30 September 2021. The business continues to progress with its clinical pipeline and trials, however the quoted share price has fallen on the back of limited trading volumes. We continue to believe that there will be long-term appreciation in the share price, as key milestones continue to be achieved.

DiA Imaging Analysis Limited (“DiA”) was reduced in value by £4,000 as at 30 September 2021, to reflect the movement in the exchange rate in the US Dollar/Sterling exchange rate, between the date of investment and the half-year date.

It is disappointing to report that we continue to anticipate no recovery of value from Live Better With Limited, a developer of a healthcare website aiming to help people with long term medical conditions.

Outlook
The two IPOs that took place in the period are reassuring signs of the quality of the companies in the Venture Capital Portfolio. These companies are now starting to drive the overall performance of the Healthcare Share pool in the right direction.

Over the remainder of the year, we will continue to focus on supporting the existing companies in the Venture Capital Portfolio, whilst also looking to further add to this portfolio in deploying existing and new fundraising proceeds. The healthcare sector is generating a good level of attractive dealflow and there is strong market sentiment towards these businesses, as we have observed with Arecor and GENinCode.

Downing LLP

Review of Investments – Healthcare Share Pool

The following investments were held at 30 September 2021:

 Cost
as at 30
September
2021
Valuation as
at 30
September
2021
Valuation
Movement
in period


% of
portfolio
Portfolio of investments£’000 £’000 £’000 
Venture Capital investments    
Arecor Therapeutics plc^1,5333,8592,32622.1%
GENinCode plc^1,2022,4191,21713.8%
Adaptix Limited1,0561,84375810.5%
Open Bionics Limited1,0001,3783787.9%
Congenica Limited1,1841,215-6.9%
FVRVS Limited (t/a Fundamental VR)7508791295.1%
Future Health Works Limited (t/a MyRecovery)528556-3.2%
Destiny Pharma plc^750545(248)3.1%
The Electrospinning Company Limited4785441243.1%
Invizius Limited500500-2.9%
DiA Imaging Analysis Limited41541942.4%
Cambridge Respiratory Innovations Limited400400-2.3%
MIP Diagnostics Limited200200-1.1%
Live Better With Limited1,106--0.0%
 11,10214,7574,68884.4%
Liquidity Investments    
Downing Strategic Micro-Cap Investment Trust plc*^729569343.3%
MI Downing UK Micro-Cap Growth Fund*4024(5)0.1%
 769593293.4%
 11,87115,3504,71787.8%
Cash at bank and in hand 2,137 12.2%
Total investments 17,487 100.0%

*non-qualifying investment
^listed and traded on the London Stock Exchange

Investment movements for the period ended 30 September 2021

 Cost
Additions £’000
Venture Capital investments 
Arecor Therapeutics plc**1,547
GENinCode plc1,202
DiA Imaging Analysis Limited415
FVRVS Limited (t/a Fundamental VR)250
The Electrospinning Company Limited200
 3,614


 CostValuation at
01/04/21*
ProceedsLoss
vs. cost
Realised
gain
Disposals£’000£’000£’000£’000£’000
Venture Capital investments     
Arecor Limited**1,5331,5331,533--
GENinCode plc900900900--
Liquidity investments     
MI Downing UK Micro-Cap Growth Fund*1168696(20)10
 2,5492,5192,529(20)10

*non-qualifying investment
**includes Loan Note conversion and share for share exchange

Investment Manager’s Report- Liquidity Investments

i.  Introduction
We present a review of the portfolios of Liquidity Investments, held by the Ventures and Healthcare Share pools, over the six-month period to 30 September 2021. As at 30 September, both Share pools had holdings in Downing Strategic Micro-Cap Investment Trust plc (‘DSM’), which performed well during the half-year period, as well as a small residual holding in MI Downing UK Micro-Cap Growth Fund, which is in the process of winding-up.

The carrying values of the Liquidity Investments have been adjusted to reflect their quoted prices as at 30 September 2021. This resulted in uplifts of £180,000 and £29,000 for the Ventures and Healthcare Share pools, respectively, for the half-year period.

ii.  Downing Strategic Micro-Cap Investment Trust plc

The values of the Ventures and Healthcare Share pool holdings in Downing Strategic Micro-Cap Investment Trust plc (“DSM”) increased in value by £196,000 and £34,000 during the period. As at 30 September 2021, DSM’s mid-market share price traded at a discount to NAV of 16.89%, representing unrealised value in the company’s share price. The Managers of DSM also believe that the trust’s portfolio also has a level of intrinsic value which is yet to be recognised by the market. They have been uncharacteristically bullish on the prospects for the portfolio throughout 2021, believing that the prospects for DSM investments
are healthy and capable of delivering earnings and cash flows which should ultimately be better than the pre-Covid period.

DSM holdings are now typically more efficient, better managed, and should be able to achieve better returns on invested capital than at initial investment. The Managers believe that the portfolio is as well positioned as it can be.

iii.  MI Downing UK Micro-Cap Growth Fund

Ventures and Healthcare Shareholders will be aware of the small residual investments in Downing Micro-Cap Growth Fund (“DMCG”). Since 19th February 2021, the ACD has been working with the investment manager Downing LLP to dispose of and liquidate all assets of the Fund with the intention of returning monies to investors at the earliest opportunity. The second round of capital distributions were made in June 2021, returning proceeds of £301,000 to the Ventures Share pool and £96,000 to the Healthcare Share pool, realising gains of £31,000 and £10,000 respectively, over the valuations as at 31 March 2021. Over 100% of the suspension price has now been returned to shareholders, with a small residual distribution expected in the coming months.

As at 30 September 2021, the Ventures Share pool’s residual holding in DMCG was reduced in value by £16,000, and the Healthcare Share pool’s holding by £5,000.

Downing LLP

Investment Manager’s Report DSO D Share Pool

Introduction
The process of realising the investments and returning funds to Shareholders remains the focus of the DSO D Share pool, although this has been subject to significant delays as a result of the coronavirus pandemic.

Net Asset Value and results
The Net Asset Value (“NAV”) per DSO D Share at 30 September 2021, net of the estimated performance incentive fee, stood at 9.9p, an increase of 0.2p over the period. Whilst the reported NAV (prior to the deduction of the performance fee estimate) reduced by 1.3p during the period, the estimated performance incentive fee, which is expected to become due to partners and staff of Downing LLP, also reduced during the period.

Total Return, net of the estimated performance fee, stands at 104.2p per share compared to initial cost to Shareholders, net of income tax relief, of 70.0p per Share. We consider this to be satisfactory performance when compared to the initial NAV of 100p.

The loss on ordinary activities after taxation for the period was £1,000, comprising a revenue loss of £8,000 and a capital gain of £7,000.

Whilst it is unfortunate to report further delays in the realisation process, the NAV of the DSO Share pool has, to date, not been adversely impacted by the effects of the coronavirus pandemic. However, we continue to experience delays in exiting from the DSO D Share pool’s investments in Pearce and Saunders and Pearce and Saunders DevCo Limited. Plans are in place to exit from these companies and we hope to have completed this process by the summer of 2022.

Venture Capital investments
As at 31 March 2021, the DSO D Share Pool held four Venture Capital investments with a total value of £455,000.

Portfolio activity
We are pleased to report that, after the half-year date, the DSO D Share pool exited from its two renewable energy investments.

Fresh Green Power Limited, the owner of solar panels on the rooftops of domestic properties in the UK, was exited after the half-year date. The carrying value of the investment was adjusted at 30 September 2021 to bring it in line with the proceeds received by the DSO D Share pool.

Green Energy Production UK Limited owns a portfolio of commercial solar panels on the rooftops of chicken sheds in Lincolnshire. The DSO D Share pool’s investment in the company has now been exited. The carrying value of this investment was also adjusted at 30 September, in line with the proceeds received shortly after the half-year date.

Portfolio valuation
During the year, the carrying value of the portfolio of Venture Capital investments held by the DSO D Share pool was increased by £10,000.

As DSO D Shareholders will be aware Pearce and Saunders Limited has been heavily impacted by the restrictions and forced closures brought about by the coronavirus pandemic. However, as restrictions have been lifted the business has been able to trade more effectively, leading to an increase in valuation of £17,000 as at 30 September 2021.

Finally, Pearce and Saunders DevCo Limited was reduced in value by £3,000 as at 30 September 2021.

Dividends
As Fresh Green Power and Green Energy Production have now been exited, the DSO D Share pool is in a position to declare a 7.5p dividend to DSO D Shareholders, to be paid on 28 January 2022, to Shareholders on the register as at 7 January 2022. This takes total dividends paid to 102.0p per DSO D Share, on a net investment of 70.0p.

Outlook
The focus for the DSO D Share pool continues to be on realising the remaining investments. A
further distribution will be paid once the final realisations have taken place.

Downing LLP

Review of investments - DSO D Share Pool

The following investments were held at 30 September 2021:

 Cost
as at 30
September
2021
Valuation
as at 30
September
2021
Valuation
Movement
in period


% of
portfolio
Portfolio of investments£’000 £’000 £’000 
Venture Capital investments    
Fresh Green Power Limited189279(3)37.0%
Pearce and Saunders Limited275941712.5%
Green Energy Production UK Limited10066(1)8.7%
Pearce and Saunders DevCo Limited*1916(3)2.1%
 5834551060.3%
Cash at bank and in hand 300 39.7%
Total investments 755 100.0%

* non-qualifying investment

All Venture Capital investments are incorporated in England and Wales.

There were no investment disposals during the period.

Investment Manager’s Report - DP67 Share Pool

Introduction
The process of realising the investments and returning funds to DP67 Shareholders remains the focus for this Share pool, although this has been subject to substantial delays as a result of the coronavirus pandemic.

Net Asset Value and results
The Net Asset Value (“NAV”) per DP67 Share at 30 September 2021 stood at 19.5p, an increase of 1.1p over the period. Total Return stands at 87.3p per DP67 Share, compared to initial cost to Shareholders, net of income tax relief, of 70.0p per Share. Compared to the initial NAV of 100p, we consider the Total Return of 87.3p to be underperformance against the original expectations for the DP67 Share pool.

The return on ordinary activities after taxation for the period was £114,000, comprising a revenue loss of £17,000 and a capital gain of £131,000.

As Shareholders are aware, the DP67 portfolio has a high level of exposure to the leisure and hospitality sector, which has been heavily impacted by the coronavirus pandemic. It has not been possible to seek to achieve good exit values for these businesses during a period in which they have been unable to operate at a level close to full capacity. We are encouraged by the trading that has been possible following the gradual lifting of restrictions throughout the UK, however we anticipate that it will still take some time for exits to be achieved, as a good level of post-pandemic trading activity will need to be demonstrated if the sales values achieved are to represent the best value for shareholders.

Venture Capital investments
As at 31 March 2021, the DP67 Share pool held a portfolio of five Venture Capital investments, with a total value of £2.3 million.

Portfolio activity
It is disappointing to report that there were no realisations during the period.

Portfolio valuation
The DP67 portfolio was increased in value by a total of £138,000 during the period. This uplift was wholly attributable to Gatewales Limited. The company is a corporate member in Fenkle Street LLP and is valued based on a discounted cash flow basis. Unwinding of the discount during the period resulted in the uplift stated.

The valuations of the remaining Venture Capital investments are unchanged from those stated in the Annual Report to 31 March 2021.

Outlook
The focus for the DP67 Share pool continues to be on realising the remaining investments. The delays in the exit processes are frustrating, however we are hopeful that these might now complete by Q4 2022. In the interim, we will continue to work with management teams in order to maximise the proceeds for the DP67 Share pool. Further dividends will be paid once the final realisations have taken place.

Downing LLP

Review of Investments – DP67 Share Pool

The following investments were held at 30 September 2021:

 



Cost




Valuation


Valuation
movement
in period


% of
portfolio
Portfolio of investments£’000 £’000 £’000 
Venture Capital investments    
Cadbury House Holdings Limited1,409791-38.2%
Fenkle Street LLP*405727-34.9%
Gatewales Limited**34374713825.5%
Yamuna Renewables Limited400--0.0%
London City Shopping Centre Limited*99--0.0%
 2,6562,26513898.6%
Cash at bank and in hand 10 1.4%
Total investments 2,275 100.0%

*non-qualifying investment                        
**partially qualifying investment

All Venture Capital investments are incorporated in England and Wales.

There were no investment disposals during the period.

Unaudited Income Statement
for the six months ended 30 September 2021

 Six months ended
30 Sep 2021
Six months ended
30 Sep 2020
 Year
ended
31 Mar
2021
    
 RevenueCapitalTotalRevenueCapitalTotal Total
 £’000£’000£’000£’000£’000£’000 £’000
Income432452342236 268
Gains on investments-7,2447,244-762762 4,816
 437,2467,289234764998 5,084
Investment management fees(244)(244)(488)(196)(196)(392) (822)
Other expenses(209)-(209)105-105 (97)
(Loss)/profit on ordinary activities before tax(410)7,0026,592143568711 4,165
Tax on total comprehensive income and ordinary activities------ 

(69)
(Loss)/profit attributable to equity Shareholders, being total comprehensive income for the period(410)7,0026,592143568711 4,096
         
Basic and diluted return per share:        
Ventures Share(0.5p)4.6p4.1p0.4p1.6p2.0p (1.8p)
Healthcare Share(0.7p)23.7p23.0p(0.1p)(0.3p)(0.4p) (0.4p)
DSO D Share(0.1p)0.1p0.0p-(1.3p)(1.3p) 8.0p
DP67 Share(0.2p)1.3p1.1p(0.1p)(0.3p)(0.4p) 2.9p

A Statement of Total Recognised Gains and Losses has not been prepared as all gains and losses are recognised in the Income Statement as noted above.

Analysed by Share pool
for the six months ended 30 September 2021

 Six months ended
30 Sep 2021
 Six months ended
30 Sep 2020
 Year
ended
31 Mar
2021
 RevenueCapitalTotal RevenueCapitalTotal Total
Ventures Share pool£’000£’000£’000 £’000£’000£’000 £’000
Income35136 1952197 232
Net gain on investments-2,3692,369 -878878 4,067
 352,3702,405 1958801,075 4,299
Investment management fees(152)(152)(304) (113)(113)(226) (514)
Other expenses(136)-(136) 90-90 (25)
(Loss)/profit on ordinary activities before tax(253)2,2181,965 172767939 3,760
Tax on total comprehensive income and ordinary activities--- --- (39)
(Loss)/profit attributable to equity Shareholders, being total comprehensive income for the period(253)2,2181,965 172767939 3,721


`Six months ended
30 Sep 2021
 Six months ended
30 Sep 2020
 Year
ended
31 Mar
2021
 RevenueCapitalTotal RevenueCapitalTotal Total
Healthcare Share pool£’000£’000£’000 £’000£’000£’000 £’000
Income819 22-22 36
Net gain on investments-4,7274,727 -88 796
 84,7284,736 22830 832
Investment management fees(82)(82)(164) (72)(72)(144) (268)
Other expenses(58)-(58) 29-29 (15)
(Loss)/profit on ordinary activities before tax(132)4,6464,514 (21)(64)(85) 549
Tax on total comprehensive income and ordinary activities--- --- -
(Loss)/profit attributable to equity Shareholders, being total comprehensive income for the period(132)4,6464,514 (21)(64)(85) 549


 Six months ended
30 Sep 2021
 Six months ended
30 Sep 2020
 Year
ended
31 Mar
2021
 RevenueCapitalTotal RevenueCapitalTotal Total
DSO D Share pool£’000£’000£’000 £’000£’000£’000 £’000
Income--- 7-7 -
Net gain/(loss) on investments-1010 -(97)(97) (106)
 -1010 7(97)(90) (106)
Investment management fees(3)(3)(6) (4)(4)(8) (12)
Other expenses(5)-(5) (6)-(6) (25)
(Loss)/profit on ordinary activities before tax(8)7(1) (3)(101)(104) (143)
Tax on total comprehensive income and ordinary activities--- --- -
(Loss)/profit attributable to equity Shareholders, being total comprehensive income for the period(8)7(1) (3)(101)(104) (143)


 Six months ended
30 Sep 2021
 Six months ended
30 Sep 2020
 Year
ended
31 Mar
2021
 RevenueCapitalTotal RevenueCapitalTotal Total
DP67 Share pool£’000£’000£’000 £’000£’000£’000 £’000
Income--- 10-10 -
Net gain/(loss) on investments-138138 -(27)(27) 59
 -138138 10(27)(17) 59
Investment management fees(7)(7)(14) (7)(7)(14) (28)
Other expenses(10)-(10) (8)-(8) (32)
(Loss)/profit on ordinary activities before tax(17)131114 (5)(34)(39) (1)
Tax on total comprehensive income and ordinary activities--- --- (30)
(Loss)/profit attributable to equity Shareholders, being total comprehensive income for the period(17)131114 (5)(34)(39) (31)

Unaudited Balance Sheet

as at 30 September 2021

 As at 30
September
2021
 As at 30
September
2020
 As at 31
March
2021
 £’000 £’000 £’000
Fixed assets     
Investments48,900 42,281 40,743
Current assets     
Debtors393 375 701
Cash at bank and in hand4,964 1,309 6,986
 5,357 1,684 7,867
Creditors: amounts falling due within one year(644) (556) (381)
Net current assets4,713 1,128 7,306
Net assets53,613 43,409 48,049
      
Capital and reserves     
Called up Share capital103 100 102
Capital redemption reserve58 58 58
Special reserve27,547 37,377 29,417
Share premium account20,919 18,930 20,010
Funds held in respect of Shares not yet allotted194 68 241
Revaluation reserve5,804 (12,610) (1,143)
Capital reserve – realised3,166 2,803 3,132
Revenue reserve(4,178) (3,317) (3,768)
Total equity Shareholders’ funds53,613 43,409 48,049
      
Basic and diluted Net Asset Value per Share:     
Ventures Share68.5p 61.2p 10.2p
Healthcare Share88.7p 65.2p 18.4p
DSO D Share10.2p 10.7p 67.2p
DP67 Share 19.5p 18.4p 68.5p

Analysed by Share pool

as at 30 September 2021

 As at 30
September
2021
 As at 30
September
2020
 As at 31
March
2021
Ventures Share pool£’000 £’000 £’000
Fixed assets     
Investments30,830 30,976 28,633
Current assets     
Debtors198 240 464
Cash at bank and in hand2,517 79 3,141
 2,715 319 3,605
Creditors: amounts falling due within one year(404) (3,070) (238)
Net current assets2,311 (2,751) 3,367
Net assets33,141 28,225 32,000
Capital and reserves     
Called up share capital60 57 59
Capital redemption reserve58 58 58
Special reserve18,997 26,082 20,195
Share premium account14,551 13,180 14,009
Funds held in respect of shares not yet allotted189 61 222
Revaluation reserve1,237 (9,322) (814)
Capital reserve – realised878 426 847
Revenue reserve(2,829) (2,317) (2,576)
Total equity Shareholders’ funds33,141 28,225 32,000


 As at 30
September
2021
 As at 30
September
2020
 As at 31
March
2021
Healthcare Share pool£’000 £’000 £’000
Fixed assets     
Investments15,350 8,806 9,538
Current assets     
Debtors194 2,882 254
Cash at bank and in hand2,137 890 3,491
 2,331 3,772 3,745
Creditors: amounts falling due within one year(187) (291) (99)
Net current assets2,144 3,481 3,646
Net assets17,494 12,287 13,184
Capital and reserves     
Called up share capital24 24 24
Special reserve7,987 10,323 8,656
Share premium account6,368 5,750 6,001
Funds held in respect of shares not yet allotted5 7 19
Revaluation reserve(4,587) (2,640) (161)
Capital reserve – realised(474) - (84)
Revenue reserve(1,403) (1,177) (1,271)
Total equity Shareholders’ funds17,494 12,287 13,184


 As at 30
September
2021
 As at 30
September
2020
 As at 31
March
2021
DSO D Share pool£’000 £’000 £’000
Fixed assets     
Investments455 458 445
Current assets     
Debtors65 82 29
Cash at bank and in hand300 312 344
 365 394 373
Creditors: amounts falling due within one year(20) (12) (17)
Net current assets345 382 356
Net assets800 840 801
Capital and reserves     
Called up share capital8 8 8
Special reserve963 972 966
Revaluation reserve(128) (132) (138)
Capital reserve – realised(37) (37) (37)
Revenue reserve(6) 29 2
Total equity Shareholders’ funds800 840 801


 As at 30
September
2021
 As at 30
September
2020
 As at 31
March
2021
DP67 Share pool£’000 £’000 £’000
Fixed assets     
Investments2,265 2,041 2,127
Current assets     
Debtors1 53 1
Cash at bank and in hand10 28 10
 11 81 11
Creditors: amounts falling due within one year(98) (65) (74)
Net current assets(87) 16 63
Net assets2,178 2,057 2,064
Capital and reserves     
Called up share capital11 11 11
Special reserve(400) - (400)
Revaluation reserve108 (516) (30)
Capital reserve – realised2,399 2,414 2,406
Revenue reserve60 148 77
Total equity Shareholders’ funds2,178 2,057 2,064

Statement of Changes in Equity

for the six months ended 30 September 2021

 Share
capital Called
up
Capital
Redemption
reserve
Special
reserve
Share
premium
account
Funds held
in respect
of Shares
not yet
allotted
Revaluation
Reserve
(Note 9)
Capital
reserve - realised
Revenue
reserve


Total
 £’000£’000£’000£’000£’000£’000£’000£’000£’000
At 31 March 2020985839,43317,971535(13,302)2,483(3,451)43,825
Total comprehensive
income
-----4,158249(311)4,096
Transfer between reserves*--(10,016)--8,0012,021(6)-
Unallotted Shares----(294)---(294)
Transactions with owners         
Dividend paid------(1,621)-(1,621)
Cancellation of shares---------
Purchase of own shares---------
Issue of shares4--2,097----2,101
Share issue costs---(58)----(58)
At 31 March 20211025829,41720,010241(1,143)3,132(3,768)48,049
Total comprehensive income-----7,203(202)(410)6,591
Transfer between reserves*--(1,845)--(256)2,101--
Unallotted Shares----(47)---(47)
Transactions with owners         
Dividend paid------(1,865)-(1,865)
Cancellation of Shares---------
Purchase of own shares--(25)-----(25)
Issue of shares1--933----934
Share issue costs---(24)----(24)
At 30 Sept 20211035827,54720,9191945,8043,166(4,178)53,613

* A transfer of (£256,000) (2021: £8,001,000) representing previously recognised realised gains and losses on disposal of investments during the period has been made between the Revaluation Reserve and the Capital reserve - realised. A transfer of £1,845,000 (2021: £10,022,000) representing the total of: realised losses on the disposal of investments, cumulative impairment losses, capital expenses and capital dividends in the period, has been made between the Capital Reserve - realised and the Special reserve. A transfer of £nil (2021: £6,000), representing the balance on the Revenue reserve relating to previously cancelled share classes, has been made from the revenue reserve to the Special reserve.

Unaudited Statement of Cash Flows
for the six months ended 30 September 2021

 DSO D
Share
pool
DP67
Share
pool
Ventures
Share
pool
Healthcare Share
pool
Total
 £’000£’000£’000£’000£’000
Cash flows from operating activities     
(Loss)/return on ordinary activities before taxation(1)1141,9654,5146,592
Gains on investments(10)(138)(2,369)(4,728)(7,245)
Increase in creditors32416488214
(Increase)/decrease in debtors(36)-26959357
Net cash (outflow)/inflow from operating activities(44)-29(67)(82)
Corporation tax paid-----
Net cash generated from operating activities(44)-29(67)(82)
Cash flow from investing activities     
Purchase of investments--(547)(3,614)(4,161)
Proceeds from disposal of investments--7192,5293,248
Net cash inflow/(outflow) from investing activities--172(1,085)(913)
Net cash (outflow)/inflow before financing(44)-201(1,152)(995)
Cash flows from financing activities     
Issue of share capital--(11)(14)(25)
Issue of share capital--556378934
Cost of issue of share capital--(14)(10)(24)
Funds held in respect of shares not yet allotted--(33)(14)(47)
Equity dividends paid--(1,323)(542)(1,865)
Net cash outflow from financing activities--(825)(202)(1,027)
      
Net change in cash(44)-(624)(1,354)(2,022)
Cash and cash equivalents at start of the year344103,1413,4916,986
Cash and cash equivalents at end of the year300102,5172,1374,964
      
Cash and cash equivalents comprise     
Cash at bank and in hand300102,5172,1374,964
Total cash and cash equivalents300102,5172,1374,964

Unaudited Statement of Cash Flows

for the six months ended 30 September 2020

 DSO D
Share
pool
DP67
Share
pool
Ventures
Share
pool
Healthcare Share
pool
Total
 £’000£’000£’000£’000£’000
Cash flows from operating activities     
(loss)/return on ordinary activities before taxation(104)(39)939(85)711
Losses/(gains) on investments9727(878)(8)(762)
(Decrease)/increase in creditors(22)(18)2,804(128)2,636
(Increase)/decrease in debtors(32)(4)202(2,875)(2,709)
Net cash (outflow)/inflow from operating activities(61)(34)3,067(3,096)(124)
Corporation tax paid-----
Net cash generated from operating activities(61)(34)3,067(3,096)(124)
Cash flow from investing activities     
Purchase of investments--(6,163)(1,639)(7,802)
Proceeds from disposal of investments101-650-751
Net cash inflow/(outflow) from investing activities101-(5,513)(1,639)(7,051)
Net cash inflow/(outflow) before financing40(34)(2,446)(4,735)(7,175)
Cash flows from financing activities     
Issue of share capital--7052951,000
Cost of issue of share capital--(29)(10)(39)
Funds held in respect of shares not yet allotted--(351)(119)(470)
Equity dividends paid--(1,150)(471)(1,621)
Net cash outflow from financing activities--(825)(305)(1,130)
      
Net change in cash40(34)(3,271)(5,040)(8,305)
Cash and cash equivalents at start of the year272623,3505,9309,614
Cash and cash equivalents at end of the year31228798901,309
      
Cash and cash equivalents comprise     
Cash at bank and in hand31228798901,309
Total cash and cash equivalents31228798901,309

Notes to the Unaudited Financial Statements

1.  General Information
Downing FOUR VCT plc (“the Company”) is a Venture Capital Trust established under the legislation introduced in the Finance Act 1995 and is domiciled in the United Kingdom and incorporated in England and Wales.

2.  Basis of accounting
The unaudited half-yearly financial results cover the six months to 30 September 2021 and have been prepared in accordance with the accounting policies set out in the statutory accounts for the year ended 31 March 2021, which were prepared in accordance with the Financial Reporting Standard 102 (“FRS 102”) and the Statement of Recommended Practice “Financial Statements of Investment Trust Companies” issued in October 2019 (“SORP”).

3.  The Company has only one class of business and derives its income from investments made in shares, securities and bank deposits.


4.  The comparative figures are in respect of the six months ended 30 September 2020 and the year ended 31 March 2021 respectively.


5.  Net Asset Value per share at the period end has been calculated on the number of shares in issue at the period end as follows:

Ventures Shares*48,107,209
Healthcare Shares*19,710,375
DSO D Shares7,867,247
DP67 Shares11,192,136

*Excludes Management Shares

6.  Return per share for the period has been calculated on the average number of shares in issue in the period as follows:

Ventures Shares*47,737,573
Healthcare Shares*19,573,094
DSO D Shares7,867,247
DP67 Shares11,192,136

*Excludes Management Shares

7.  The unaudited financial statements set out herein do not constitute statutory accounts within the meaning of Section 434 of the Companies Act 2006 and have not been delivered to the Registrar of Companies.


8.  Dividends

 Six months ended 30 September 2021
 Pence per Share Revenue
£’000
Capital
£’000
Total
£’000
Ventures Shares     
Paid     
Final (year ended 31 March 2021)2.75 -1,3231,323
Healthcare Shares     
Paid     
Final (year ended 31 March 2021)2.75 -542542

9.  Reserves

 30 Sep 202130 Sep 202031 Mar 2021
 £’000£’000£’000
Capital redemption reserve585858
Special reserve27,54737,37729,417
Share premium account20,91918,93020,010
Revaluation reserve5,804(12,610)(1,143)
Capital reserve – realised3,1662,8033,132
Revenue reserve(4,178)(3,317)(3,768)
Funds held in respect of shares not yet allotted19468241
 53,51043,30947,947

The Revenue reserve, Special reserve and Capital reserve - realised are distributable reserves and are reduced by revaluation losses of £11.8 million. Distributable reserves at 30 September 2021 were £14.6 million.

10.    Fixed assets – investments

 Liquidity
investments
Quoted VC investmentsUnquoted VC investments

Total
 £’000£’000£’000£’000
Opening cost at 1 April 20215,6461,25042,37449,270
Unrealised (losses)/gains at 1 April 2021(1,497)72548(877)
Unrealised foreign exchange losses at 1 April 2021--(266)(266)
Impairment losses at 1 April 2021--(7,384)(7,384)
Opening fair value at 1 April 20214,1491,32235,27240,743
Movements in the year:    
Purchased at cost-3,1719904,161
Disposals - proceeds(397)(2,851)-(3,248)
        - realised gains on disposals41--41
Unrealised foreign exchange gains--7979
Unrealised gains in the Income Statement2093,7643,1517,124
Transfers between investment categories-2,833(2,833)-
Closing value at 30 Sept 20214,0028,23936,65948,900
Closing cost at 30 Sept 20215,1614,40339,79049,354
Unrealised (losses)/gains at 30 Sept 2021(1,159)3,8363,3135,990
Unrealised foreign exchange losses at 30 Sept 2021--(187)(187)
Impairment losses at 30 Sept 2021--(6,257)(6,257)
Closing value at 30 Sept 20214,0028,23936,65948,900

The fair value of investments is determined using the detailed accounting policy as shown in the audited financial statements for the year ended 31 March 2021. The Company has categorised its financial instruments using the fair value hierarchy as follows:

Level 1        Reflects financial instruments quoted in an active market (quoted companies, investment funds and fixed interest bonds);
Level 2        Reflects financial instruments that have prices that are observable either directly or indirectly; and
Level 3        Reflects financial instruments that use valuation techniques that are not based on observable market data (investments in unquoted shares and loan note investments).

 Level 1Level 2Level 330 Sept 2021 Level 1Level 2Level 331 Mar 2021
 £’000£’000£’000£’000 £’000£’000£’000£’000
Liquidity investments4,002--4,002 4,149--4,149
Quoted equity8,239--8,239 1,322--1,322
Unquoted loan notes--3,6673,667 --3,6673,667
Unquoted equity--32,99232,992 --31,60531,605
 12,241-36,65948,900 5,471-35,27240,743

11.  Risk and uncertainties
Under the Disclosure and Transparency Directive, the Board is required in the Company’s half-year results to report on the principal risks and uncertainties facing the Company over the remainder of the financial year.

The Board has concluded that the key risks facing the Company over the remainder of the financial period are as follows:

(i)      compliance risk of failure to maintain approval as a VCT;
(ii)      market, liquidity and counterparty risk associated with Public Equity investments; and
(iii)      investment risk associated with investing in small and immature businesses.

The Company’s compliance with the VCT regulations is continually monitored by the Manager, who reports regularly to the Board on the current position. The Company also retains Philip Hare & Associates LLP (“Philip Hare”) to provide regular reviews and advice in this area. Philip Hare has confirmed that all relevant tests have been complied with for the period under review. The Board considers that this approach reduces the risk of a breach of the VCT regulations.

With this approach, the Board believes that these risks are reduced.

In order to make VCT qualifying investments, the Company has to invest in small businesses which are often immature. It also has a limited period in which it must invest the majority of its funds into VCT qualifying investments. The Manager follows a rigorous process in vetting and carefully structuring new investments, including taking a charge over the assets of the business wherever possible and, after an investment is made, closely monitoring the business.

12.  Going concern

The Directors have reviewed the Company’s financial resources at the period end and conclude that the Company is well placed to manage its business risks.

The Board confirms that it is satisfied that the Company has adequate resources to continue in business for the foreseeable future. For this reason, the Board believes that the Company continues to be a going concern and that it is appropriate to apply the going concern basis in preparing the financial statements.

13.  The Directors confirm that, to the best of their knowledge, the Half-Yearly Report has been prepared in accordance with the “Statement: Half-Yearly Financial Reports” issued by the UK Accounting Standards Board as well as in accordance with FRS 104 Interim Financial Reporting and the half-yearly financial report includes a fair review of the information required by:

  1. DTR 4.2.7R of the Disclosure and Transparency Rules, being an indication of important events that have occurred during the first six months of the financial year and their impact on the condensed set of financial statements, and a description of the principal risks and uncertainties for the remaining six months of the year; and
  2. DTR 4.2.8R of the Disclosure and Transparency Rules, being related party transactions that have taken place in the first six months of the current financial year and that have materially affected the financial position or performance of the entity during that period, and any changes in the related party transactions described in the last annual report that could do so.

14.  Copies of the Half-Yearly Report will be sent to Shareholders shortly. Further copies can be obtained from the Company’s registered office or downloaded from www.downing.co.uk